Cresco Labs Q2 Earnings: Why Operating Performance, Not Just Revenue Growth, Stood Out

Cresco Labs (CSE: CL) (OTCQX: CRLBF) reported second-quarter revenue of $173 million, gross profit of $87 million, adjusted EBITDA of $40 million, and $15 million in net income on Thursday, delivering one of the stronger earnings reports among U.S. cannabis operators this quarter. While the headline numbers were solid, the bigger story for investors is that profitability appears to be improving alongside growth rather than because of it.

Three Numbers That Defined Cresco’s Quarter

Revenue increased to $173 million, reflecting 15% sequential growth, indicating that recent acquisitions and market expansion are translating into higher sales.

Adjusted gross margin reached 51.6%, a level few large U.S. cannabis operators have consistently maintained as wholesale prices remain under pressure in several mature markets. This suggests Cresco continues to generate healthy economics before corporate expenses are considered.

Adjusted EBITDA increased to $40 million, producing an EBITDA margin of 22.8%. More importantly, EBITDA grew faster than revenue during the quarter. This could indicate the business is becoming more efficient.

Cost Discipline Is Beginning to Show

Cresco’s results suggest management is beginning to capture greater operating leverage.

Selling, general and administrative expenses represented 36.5% of revenue, or 32.0% on an adjusted basis after excluding one-time costs associated with acquisitions, uplisting preparations and federal reform initiatives.

Those adjustments deserve scrutiny, but even accounting for them, the relationship between revenue growth and EBITDA growth points to a business that is improving operationally.

Pennsylvania Is Becoming an Important Earnings Driver

Management pointed to Pennsylvania as one of the quarter’s strongest operational stories.

The company said the nine dispensaries acquired in Pennsylvania increased gross profit by 11% during their first full quarter under Cresco’s ownership, even before any locations were rebranded.

That matters because acquisitions ultimately succeed or fail based on integration, not purchase price.

Ohio also continued to perform well, with newly opened Sunnyside dispensaries ranking among the state’s strongest new stores according to management. At the same time, Kentucky generated its first branded product revenue during June as the company entered commercial operations.

Net Income Looks Better, but Investors Should Understand Why

Cresco reported $15 million in net income after posting losses of $17 million in the first quarter of 2026 and $88.9 million in the fourth quarter of 2025. The swing reflects a combination of stronger operating performance and a more favorable tax environment following federal rescheduling, underscoring the importance of separating operational improvements from regulatory tailwinds for investors.

Part of that improvement reflects changing federal tax treatment following cannabis rescheduling, something management addressed directly during its prepared remarks. Eliminating the burden of Section 280E has the potential to improve reported earnings across the sector while strengthening balance sheets and increasing access to institutional capital.

However, investors should avoid attributing the entire improvement to tax policy. Cresco also delivered stronger gross margins and higher EBITDA. Those are operational gains that would remain relevant even in the absence of regulatory reform.

Capital Allocation Remains the Next Test

The next question is how much financial flexibility management has to capitalize on future opportunities.

At the end of the quarter, Cresco held $67 million in cash, cash equivalents, and restricted cash, while carrying approximately $330 million of debt, consisting primarily of its senior secured term loan.

The balance sheet appears stable, but it does not provide unlimited flexibility. Management will likely need to continue balancing debt management, selective expansion, and investment in existing operations rather than pursuing aggressive acquisitions.

That approach may prove appropriate as the industry transitions into a post-rescheduling environment where capital markets could gradually reopen, and acquisition opportunities remain plentiful.}

The earnings release also leaves several important questions unanswered. Investors will likely want more clarity on how much of the 15% sequential revenue growth was driven by the Pennsylvania acquisition versus organic expansion, whether the current balance sheet leaves room for additional acquisitions or favors debt reduction, and how much of this quarter’s improvement in net income is likely to be sustainable in future periods.

The Investor Takeaway

Revenue growth was encouraging, but the more meaningful development was the combination of healthy gross margins, expanding EBITDA and early signs that Cresco’s integration strategy is producing results, as management reported higher gross profit at the recently acquired Pennsylvania dispensaries.

Those factors point to a business generating better returns from its existing operations rather than relying solely on external catalysts.

The quarter also leaves investors with several financial metrics to monitor in the months ahead.

SG&A totaled $63 million, or 36.5% of revenue, while adjusted SG&A declined to $55 million, or 32.0% of revenue, after excluding one-time costs related to acquisitions, uplisting preparations and federal reform.

That level of expense control helped Cresco convert $87 million in gross profit into $40 million of adjusted EBITDA, representing a 22.8% EBITDA margin, before ultimately reporting $15 million in net income.

While those figures suggest improving operating efficiency, the company did not quantify how much of its return to profitability reflected stronger execution versus the benefit of changing federal tax treatment. As Cresco moves through the second half of the year, investors will likely be watching whether the company can continue expanding EBITDA and net income while keeping operating expenses under control.